These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28748442)

  • 1. Targeted Therapy and Local Control: The Dynamic Duo.
    Mamtani A; King TA
    Ann Surg Oncol; 2017 Oct; 24(11):3110-3112. PubMed ID: 28748442
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant trastuzumab in early HER2-positive breast cancer: Journeying towards the optimal duration of therapy in South Africa.
    Wiseman RJ; Riddin J; Jugathpal J; Parrish AJ; Ruff P; Blockman M
    S Afr Med J; 2020 Mar; 110(4):271-273. PubMed ID: 32657737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
    Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
    [No Abstract]   [Full Text] [Related]  

  • 4. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer.
    Jasra S; Opyrchal M; Norton L; Mehta R
    Clin Breast Cancer; 2017 Feb; 17(1):e37-e41. PubMed ID: 27665021
    [No Abstract]   [Full Text] [Related]  

  • 5. Is trastuzumab as a single agent obsolete in early breast cancer? No.
    Bianchini G
    Breast; 2019 Feb; 43():142-145. PubMed ID: 30578129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype.
    McGuire A; Lowery AJ; Kell MR; Kerin MJ; Sweeney KJ
    Ann Surg Oncol; 2017 Oct; 24(11):3124-3132. PubMed ID: 28755141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery.
    Botteri E; Veronesi P; Vila J; Rotmensz N; Galimberti V; Thomazini MV; Viale G; Orecchia R; Goldhirsch A; Gentilini O
    Br J Surg; 2017 Dec; 104(13):1802-1810. PubMed ID: 28791694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in residual disease after neoadjuvant treatment might determine sensitivity to trastuzumab emtansine.
    Altundag K
    J BUON; 2019; 24(4):1736. PubMed ID: 31646835
    [No Abstract]   [Full Text] [Related]  

  • 9. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
    Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
    Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 11. Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.
    Horton JK; Jagsi R; Woodward WA; Ho A
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):23-37. PubMed ID: 29254776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.
    Parham DM; Pinder SE
    Histopathology; 2017 May; 70(6):1009-1011. PubMed ID: 27943389
    [No Abstract]   [Full Text] [Related]  

  • 13. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
    Shammas RL; Cho EH; Glener AD; Poveromo LP; Mundy LR; Greenup RA; Blackwell KL; Hollenbeck ST
    J Am Coll Surg; 2017 Dec; 225(6):731-739.e1. PubMed ID: 28985927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
    Xu QQ; Pan B; Wang CJ; Zhou YD; Mao F; Lin Y; Guan JH; Shen SJ; Zhang XH; Xu YL; Zhong Y; Wang XJ; Zhang YN; Sun Q
    Oncotarget; 2016 Sep; 7(39):63571-63582. PubMed ID: 27566580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.
    van der Leij F; van Werkhoven E; Bosma S; Linn SC; Rutgers EJ; van de Vijver MJ; Bartelink H; Elkhuizen PHM; Scholten A
    Breast; 2016 Dec; 30():19-25. PubMed ID: 27587341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.
    Ejlertsen B; Offersen BV; Overgaard J; Christiansen P; Jensen MB; Kroman N; Knoop AS; Mouridsen H
    Acta Oncol; 2018 Jan; 57(1):3-12. PubMed ID: 29205077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.